I wouldnt be so sure about that quite yet. The NR2F6 gene is the one that was in the news earlier this month and being studied at the John Wayne Cancer Institute now for human use. Christine Ichim has the history with this with feline cancer. When it was first announced she would be working for Koos see below with NR2F6.
Harry Lander is now the key to drive business success and PPS value with the company. Business development is not a Koos forte hence Lander and at this point. Koos has been good at scientific team development and and identification of therapies.
So an announcement about feline or canine NR2F6 therapy could come out of nowhere.
When C Ichim was announced:
The focus of the NR2F6 gene is leukemia which previously stated is Dr Ichims' focus along in feline cancer along with treating cancer in dogs.
While at the University of Toronto, Dr. Ichim began developing research for the treatment of feline leukemia. Dr. Ichim has published her research in peer reviewed journals on immunological therapies for treating cancer. David Koos, Chairman & CEO of Entest BioMedical Inc. noted, "Dr. Ichim has a unique approach to treating leukemia and cancer. She is focused on cell senescence of cancer stem cells. This approach involves forcing cells that would normally become cancerous into a state of maturation where they no longer have the capacity to grow. Cancer cells typically have the ability to expand leading to life threatening conditions such as lung cancer. In this cell senescence approach, these cancer cells are no longer capable of expansion, thus rendering these cells harmless."
Dr. Ichim stated, "I am extremely excited about having the opportunity to apply my knowledge of cancer stem cells to treating leukemia in cats and cancer in dogs. While I was conducting research at the University of Toronto, I developed a model of treating cancer through forcing senescence in cancer stem cells. The next step is to develop animal therapies utilizing this model in veterinary treatments."
A spokesperson for the Company noted that it has spent an extensive period of time evaluating the most effective way to move forward in developing veterinary therapeutics. The Company believes that Dr. Ichim will be instrumental in this endeavor.
AI
